ERBB2 and breast carcinoma: In the early phase I NCT04088032 trial, 10 patients with locally advanced ER+ HER2- breast cancer will be treated with Abemaciclib, AI, and the programmed death-ligand 1 (PD-L1) inhibitor Durvalumab (MEDI4736).